An Open-Label Trial of Sildenafil Addition in Risperidone-Treated Male Schizophrenia Patients With Erectile Dysfunction
J Clin Psychiatry 2004;65(1):97-103
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Sexual dysfunction frequently occurs
in treated and untreated patients with schizophrenia. Sildenafil
is used for treatment of erectile dysfunction caused by diverse
factors. The aim of our study was to evaluate its potential
value, safety, and effect on compliance with antipsychotic
medications in risperidone-treated male schizophrenia patients
suffering from erectile dysfunction.
Method: In a 6-week open-label trial, sildenafil
was administered to 12 male schizophrenia (DSM-IV) patients,
treated with risperidone and reporting erectile dysfunction. The
starting dose was 25 mg with the possibility to increase the dose
to 75 mg. Three patients who did not respond stopped sildenafil
treatment after 3 weeks. The effect on sexual function was
assessed by the International Index of Erectile Function and the
Valevski-Weizman Male Sexual Function scale.
Results: Nine (75%) of the 12 patients completed
the 6-week trial, and 3 patients (25%) stopped taking sildenafil
after 3 weeks due to lack of response. We observed statistically
significant improvements in all sexual function domains (desire,
erectile function, orgasmic function, intercourse satisfaction,
and overall satisfaction) in the 9 patients who completed the
trial and in most of the domains for all 12 study participants.
More than half (8/12; 67%) of the patients exhibited partial or
Conclusion: Sildenafil is a useful agent
for the treatment of erectile dysfunction in risperidone-treated
male schizophrenia patients.